PACAP38 dose-response pilot study in migraine patients
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
PACAP38 dose-response pilot study in migraine patients. / Vollesen, Anne Luise Haulund; Guo, Song; Ashina, Messoud.
I: Cephalalgia : an international journal of headache, Bind 37, Nr. 4, 15.04.2017, s. 391-395.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - PACAP38 dose-response pilot study in migraine patients
AU - Vollesen, Anne Luise Haulund
AU - Guo, Song
AU - Ashina, Messoud
PY - 2017/4/15
Y1 - 2017/4/15
N2 - Background Intravenous infusion of 10 pmol/kg/min pituitary adenylate cyclase-activating polypeptide-38 (PACAP38) induces migraine-like attacks in migraine patients without aura (MO). Here, we conducted a pilot study and investigated if lower doses of PACAP38 exert similar migraine-inducing abilities. Methods We randomly allocated six MO patients to receive intravenous infusion of 4, 6, and 8 pmol/kg/min of PACAP38 over 20 minutes in a double-blind, three-way cross-over study. Headache and migraine characteristics were recorded during hospital (0-2 hours) and post-hospital (2-13 hours) phases. Results PACAP38 induced migraine-like attacks in one out of six patients with 4 pmol, two out of six patients with 6 pmol and three out of six patients with 8 pmol ( p = 0.368). All patients reported head pain after 8 pmol/kg/min, whereas five of six participants reported head pain after both 4 and 6 pmol/kg/min. We found no difference between the three doses in the AUC for headache intensity over the 12-hour observation period ( p = 0.142). An exploratory analysis showed a significant difference between 4 pmol and 8 pmol ( p = 0.031). Conclusion A trend of a dose-response relationship between dose of PACAP38 and incidence of migraine was observed. We suggest that 10 pmol/kg/min PACAP38 is the most optimal dose to induce migraine-like attacks.
AB - Background Intravenous infusion of 10 pmol/kg/min pituitary adenylate cyclase-activating polypeptide-38 (PACAP38) induces migraine-like attacks in migraine patients without aura (MO). Here, we conducted a pilot study and investigated if lower doses of PACAP38 exert similar migraine-inducing abilities. Methods We randomly allocated six MO patients to receive intravenous infusion of 4, 6, and 8 pmol/kg/min of PACAP38 over 20 minutes in a double-blind, three-way cross-over study. Headache and migraine characteristics were recorded during hospital (0-2 hours) and post-hospital (2-13 hours) phases. Results PACAP38 induced migraine-like attacks in one out of six patients with 4 pmol, two out of six patients with 6 pmol and three out of six patients with 8 pmol ( p = 0.368). All patients reported head pain after 8 pmol/kg/min, whereas five of six participants reported head pain after both 4 and 6 pmol/kg/min. We found no difference between the three doses in the AUC for headache intensity over the 12-hour observation period ( p = 0.142). An exploratory analysis showed a significant difference between 4 pmol and 8 pmol ( p = 0.031). Conclusion A trend of a dose-response relationship between dose of PACAP38 and incidence of migraine was observed. We suggest that 10 pmol/kg/min PACAP38 is the most optimal dose to induce migraine-like attacks.
KW - Adult
KW - Cross-Over Studies
KW - Dose-Response Relationship, Drug
KW - Double-Blind Method
KW - Female
KW - Humans
KW - Infusions, Intravenous
KW - Male
KW - Middle Aged
KW - Migraine without Aura
KW - Pilot Projects
KW - Pituitary Adenylate Cyclase-Activating Polypeptide
KW - Vasodilator Agents
KW - Young Adult
KW - Journal Article
KW - Randomized Controlled Trial
U2 - 10.1177/0333102416644435
DO - 10.1177/0333102416644435
M3 - Journal article
C2 - 27084887
VL - 37
SP - 391
EP - 395
JO - Cephalalgia
JF - Cephalalgia
SN - 0800-1952
IS - 4
ER -
ID: 185686271